Clinical trial No longer in our active list Phase2; Phase3 Interventional Ages 18 to 75

Evaluating BHV-7000 for treating refractory focal epilepsy in adults

Official title: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Run by Biohaven Pharmaceuticals, Inc. · NCT06309966 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new drug called BHV-7000 to see if it can help adults with hard-to-treat focal epilepsy who haven't found relief from other treatments.

More Focal Epilepsy trials Research outlook What's coming for Epilepsy: the next 6 months to 5 years

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment390 (estimated)
SponsorBiohaven Pharmaceuticals, Inc.
Industry-sponsored
Locations174 sites (Birmingham, Alabama and 173 other locations)
Trial IDNCT06309966 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 75 with a diagnosis of refractory focal onset epilepsy and a history of inadequate response to multiple anti-seizure medications.

Probably not a fit

Patients with a history of status epilepticus or those who do not meet the criteria for refractory epilepsy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness and safety of BHV-7000 in adults suffering from refractory focal onset epilepsy. Participants will receive either the investigational drug or a placebo, and their responses will be monitored over time. The study includes individuals aged 18 to 75 who have a history of focal seizures and have not achieved seizure freedom despite previous treatments. The goal is to determine if BHV-7000 can provide a new therapeutic option for this challenging condition.

Why it matters

Potential benefit: If successful, this treatment could offer a new hope for patients with refractory focal epilepsy who have limited options.

How similar studies have gone: Other studies have explored treatments for refractory epilepsy, but the specific approach with BHV-7000 is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

1. Male and Female participants 18 to 75 years of age at time of consent.
2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.

   a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures with clinically observable signs and/or symptoms iii. Focal to bilateral tonic-clonic seizures
3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
4. Ability to keep accurate seizure diaries
5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total

Key Exclusion Criteria:

1. History of status epilepticus (convulsive status epilepticus for \> 5 minutes or focal status epilepticus with impaired consciousness for \> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase.
3. Resection neurosurgery for seizures \<4 months prior to the screening visit.
4. Radiosurgery performed \<2 years prior to the screening visit.
5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms.
6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator

Where it's running

  • Onyx Clinical Trials
    Peoria, Arizona, United States
    Recruiting
  • Xenoscience, Inc.
    Phoenix, Arizona, United States
    Recruiting
  • University of Arizona / Banner University Medical Center Phoenix
    Phoenix, Arizona, United States
    Recruiting
  • ARENSIA Exploratory Medicine
    Phoenix, Arizona, United States
    Recruiting
  • Clinical Trials, Inc.
    Little Rock, Arkansas, United States
    Recruiting
  • Tri Valley Neurology Medical Associates, Inc.
    Mission Hills, California, United States
    Recruiting
Show 44 more locations
  • Profound Research LLC
    Poway, California, United States
    Recruiting
  • UConn Health
    Farmington, Connecticut, United States
    Recruiting
  • Nova Clinical Research, LLC
    Bradenton, Florida, United States
    Recruiting
  • Las Mercedes Medical Research
    Hialeah, Florida, United States
    Recruiting
  • Coral Clinic Research
    Homestead, Florida, United States
    Recruiting
  • Y&L Advance Health Care, Inc d/b/a Elite Clinical Research
    Miami, Florida, United States
    Recruiting
  • Serenity Research Center
    Miami, Florida, United States
    Recruiting
  • Research Institute of Orlando
    Orlando, Florida, United States
    Recruiting
  • Comprehensive Neurology Clinic
    Orlando, Florida, United States
    Recruiting
  • Panhandle Research & Medical Clinic
    Pensacola, Florida, United States
    Recruiting
  • Knight Neurology
    Rockledge, Florida, United States
    Recruiting
  • Encore Medical Research of Weston LLC.
    Weston, Florida, United States
    Recruiting
  • Accelerated Clinical Trials, LLC
    Peachtree Corners, Georgia, United States
    Recruiting
  • Bluegrass Epilepsy Research
    Lexington, Kentucky, United States
    Recruiting
  • DelRicht Research
    Baton Rouge, Louisiana, United States
    Recruiting
  • Neurocare Of Louisiana
    Covington, Louisiana, United States
    Recruiting
  • University Medical Center New Orleans
    New Orleans, Louisiana, United States
    Recruiting
  • DelRicht Research
    New Orleans, Louisiana, United States
    Recruiting
  • LSU Health Shreveport
    Shreveport, Louisiana, United States
    Recruiting
  • Johns Hopkins University
    Baltimore, Maryland, United States
    Recruiting
  • Boston Clinical Trials
    Boston, Massachusetts, United States
    Recruiting
  • Boston Neuro Research
    South Dartmouth, Massachusetts, United States
    Recruiting
  • SRI International
    Plymouth, Michigan, United States
    Recruiting
  • University of Missouri Health Care
    Columbia, Missouri, United States
    Recruiting
  • Somnos Clinical Research
    Lincoln, Nebraska, United States
    Recruiting
  • Nereg
    Hackensack, New Jersey, United States
    Recruiting
  • Tekton Research
    Marlboro, New Jersey, United States
    Recruiting
  • Dent Neurosciences Research Center
    Amherst, New York, United States
    Recruiting
  • Northwell Health
    Great Neck, New York, United States
    Recruiting
  • NYU Langone Health
    New York, New York, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York, United States
    Recruiting
  • Premier Health
    Dayton, Ohio, United States
    Recruiting
  • Oregon Neurology Associates
    Springfield, Oregon, United States
    Recruiting
  • Ahn
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • Musc
    Charleston, South Carolina, United States
    Recruiting
  • Le Bonheur Children's Hospital
    Memphis, Tennessee, United States
    Recruiting
  • Horizon Clinical Research Group
    Cypress, Texas, United States
    Recruiting
  • M3 Wake Research-Dallas
    Dallas, Texas, United States
    Recruiting
  • ANESC Research
    El Paso, Texas, United States
    Recruiting
  • UTHealth Houston
    Houston, Texas, United States
    Recruiting
  • Uthsc
    Houston, Texas, United States
    Recruiting
  • Stryde Research
    Plano, Texas, United States
    Recruiting
  • Intermountain Health
    Murray, Utah, United States
    Recruiting
  • Medstar Health Research Institute
    McLean, Virginia, United States
    Recruiting

+124 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • High-density flexible microneuroelectrode mapping to guide epilepsy surgery

    This study tests whether using high-density flexible microelectrocorticography during surgery helps guide the resection of the epileptogenic zone in people with drug-resistant focal epilepsy.

    Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07656857

  • RAP-219 for adults with focal seizures

    This study tests whether RAP-219 can reduce how often focal seizures happen in adults with focal epilepsy, compared with a placebo.

    Recruiting at 14 sites Phase 3 Rapport Therapeutics Inc. · Huntsville, Alabama and 13 other locations · NCT07594119

  • Spatial scene memory testing for people with temporal lobe epilepsy having surgery

    This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.

    Recruiting at 2 sites University of California, Davis · Sacramento, California and 1 other locations · NCT07580183

  • RAP-219 in adults with focal seizures

    This study tests whether RAP-219 can safely reduce the number of focal seizures in adults with focal epilepsy compared with placebo.

    Recruiting at 24 sites Phase 3 Rapport Therapeutics Inc. · Birmingham, Alabama and 23 other locations · NCT07563881

  • Probenecid for cluster seizures during presurgical epilepsy monitoring

    This trial tests whether probenecid can help control clusters of seizures in people with focal epilepsy during presurgical video-EEG monitoring.

    Recruiting Phase 2 Fondation Ophtalmologique Adolphe de Rothschild · Paris and 1 other locations · NCT07318870

  • Long-term daily CB03-154 treatment for focal epilepsy

    This extension will try once-daily CB03-154 (up to 20 mg) in people with focal epilepsy who completed the prior Phase 2 study to see if it is safe, tolerated, and helps control seizures over up to two years.

    Recruiting Phase 2 Shanghai Zhimeng Biopharma, Inc. · Melbourne, Victoria · NCT07238868

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.